Bank Julius Baer & Co. Ltd Zurich Invests $6.04 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bank Julius Baer & Co. Ltd Zurich acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 65,070 shares of the medical equipment provider’s stock, valued at approximately $6,037,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Raymond James Financial Inc. bought a new position in Lantheus in the 4th quarter worth $36,183,000. Arizona State Retirement System boosted its holdings in Lantheus by 0.9% in the 4th quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider’s stock worth $1,801,000 after buying an additional 178 shares during the period. Assetmark Inc. boosted its holdings in Lantheus by 10.0% in the 4th quarter. Assetmark Inc. now owns 69,059 shares of the medical equipment provider’s stock worth $6,178,000 after buying an additional 6,257 shares during the period. Victory Capital Management Inc. boosted its holdings in Lantheus by 13.4% in the 4th quarter. Victory Capital Management Inc. now owns 87,130 shares of the medical equipment provider’s stock worth $7,795,000 after buying an additional 10,297 shares during the period. Finally, Keybank National Association OH bought a new position in Lantheus in the 4th quarter worth $27,526,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Lantheus Trading Up 6.1 %

Shares of NASDAQ:LNTH opened at $106.34 on Monday. Lantheus Holdings, Inc. has a 12 month low of $56.44 and a 12 month high of $126.89. The company has a 50-day moving average price of $90.71 and a 200 day moving average price of $96.82. The company has a market cap of $7.28 billion, a price-to-earnings ratio of 17.69 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.